Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Verekitug Phase 2 Trial Shows 56% Asthma Exacerbation Reduction

Summary by Daily-tribune.com
Upstream Bio presents Phase 2 VALIANT trial results for verekitug in severe asthma, showing a 56% reduction in exacerbations. Phase 3 trials planned for Q1 2027.

2 Articles

Enid News & EagleEnid News & Eagle
Lean Left

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of ...

– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma –

Read Full Article
daily-tribune.comdaily-tribune.com

Verekitug Phase 2 Trial Shows 56% Asthma Exacerbation Reduction

Upstream Bio presents Phase 2 VALIANT trial results for verekitug in severe asthma, showing a 56% reduction in exacerbations. Phase 3 trials planned for Q1 2027.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

daily-tribune.com broke the news on Tuesday, September 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Enid icon

Enid

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal